'Moderna Wins Case In Patent Dispute With Pfizer And BioNTech Over Covid Jab; Decision Is A Boon For The mRNA-Vaccine Maker In Its Legal Fight To Recoup Pandemic Profits From Rivals' - Financial Times
Portfolio Pulse from Benzinga Newsdesk
Moderna has won a case at the European Patent Office in its dispute with Pfizer and BioNTech over its Covid-19 vaccine, boosting its legal fight to recoup pandemic profits. The EPO upheld the validity of one of Moderna's key patents, which could influence ongoing litigation in various European courts.
May 17, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioNTech faces a setback as the European Patent Office upholds the validity of a key Moderna patent, which could impact ongoing litigation and potential financial liabilities.
The EPO's decision to uphold Moderna's patent could lead to financial liabilities for BioNTech if courts rule in favor of Moderna in ongoing litigation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
NEGATIVE IMPACT
Pfizer faces a setback as the European Patent Office upholds the validity of a key Moderna patent, which could impact ongoing litigation and potential financial liabilities.
The EPO's decision to uphold Moderna's patent could lead to financial liabilities for Pfizer if courts rule in favor of Moderna in ongoing litigation.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Moderna's victory in the European Patent Office over a key patent dispute with Pfizer and BioNTech boosts its position in ongoing litigation to recoup pandemic profits.
The EPO's decision to uphold the validity of Moderna's patent strengthens its legal position in ongoing disputes with Pfizer and BioNTech, potentially leading to financial gains from settlements or court rulings.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100